SNSE Sensei Biotherapeutics

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi’s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL.

About Sensei Biotherapeutics  

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit , and follow the company on X @SenseiBio and .

Investor Contact:

Michael Biega

Senior Director, Investor Relations

Sensei Biotherapeutics

Media Contact:

Joyce Allaire

LifeSci Advisors



EN
27/11/2024

Underlying

SNSESensei Biotherapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sensei Biotherapeutics

 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare...

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi’s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL. About Sensei Biotherapeutics  Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and developme...

3h / 41m 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results an...

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients...

November 14, 2024 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferenc...

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences. Conference and Presentation Details: PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain Title: Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Act...

October 29, 2024 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the C...

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Ha...

September 4, 2024 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics to Present at Upcoming Conferences

Sensei Biotherapeutics to Present at Upcoming Conferences BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024: H.C. Wainwright 26th Annual Global Investment ConferenceCorporate PresentationMonday, September 9, 2024, at 7:00 a.m. ET. Virtual and New York, NY 2024 Cantor Fitzgerald Global Healthcare ConferenceFireside Chat...

September 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch